We recently published a list of the 10 Best Rising Penny Stocks to Buy According to Analysts. In this article, we are going ...

Regulus Therapeutics Inc.’s RGLS share price has surged by 7.85%, which has investors questioning if this is right time to ...

Overview: Regulus Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing drugs targeting microRNAs to treat various diseases in the United States ...

These data suggest that farabursen has the potential to be an important addition to the limited therapeutic options for patients with ADPKD," said Jay Hagan, CEO of Regulus Therapeutics.

Overview: Regulus Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing drugs targeting microRNAs to treat various diseases in the United States, with a ...

Fintel reports that on March 27, 2025, Wells Fargo upgraded their outlook for Regulus Therapeutics (NasdaqCM:RGLS) from Equal-Weight to Overweight. Analyst Price Forecast Suggests 607.38% Upside ...

Shares of Regulus Therapeutics (NASDAQ:RGLS) spiked on Thursday after the microRNA-focused drug developer announced additional topline data from a Phase 1b trial for its lead asset, farabursen ...

Also Read: Why Is Kidney Disease-Focused Regulus Therapeutics Stock Trading Higher On Tuesday? The full cohort of 26 patients demonstrated a similar mechanistic response based on urinary PC1 and ...

Explore Regulus Therapeutics stock price, quotes, charts and forecasts with Benzinga. Stay updated on market trends for RGLS. Regulus Therapeutics Stock Shoots Higher After Positive Results From ...

Investing.com -- Shares of Regulus Therapeutics (NASDAQ:RGLS) soared 23.3% today following the announcement of successful results from its Phase 1b multiple ascending dose (MAD) clinical trial of ...